In immune-mediated inflammatory diseases, the overall risk for serious adverse events is not notably higher with combo therapy than with monotherapy, though some combinations may pose increased risk.
The incidence of serious adverse events did not differ significantly between combo therapy and monotherapy in patients with immune-mediated inflammatory diseases. However, specific combinations such as abatacept with Janus kinase inhibitors may be associated with increased risks.
Researchers conducted an observational study using the health data repository from the largest hospital in Europe to describe the real-life use and safety concerns of combo therapies in several immune-mediated inflammatory diseases. They included 125 patients with immune-mediated inflammatory diseases who received 131 combo therapies . Frequently occurring immune-mediated inflammatory diseases were inflammatory bowel disease , followed by connective tissue diseases , inflammatory myopathies , and vasculitis .The primary endpoint was the occurrence of serious adverse events, including severe infections, major cardiovascular events, neoplasia, and all-cause mortality.After a median follow-up duration of 15 months, 85 patients on combo therapy did not experience any serious adverse events, and 30 patients experienced 54 episodes of severe infections; seven patients died. The 1-year cumulative incidence rates of serious adverse events and serious infections were not significantly different between combo therapy and monotherapy groups after adjustment for glucocorticoid intake and previous history of infections. Patients who received combo therapy containing tumor necrosis factor inhibitors had a higher risk for severe infections than control patients who received monotherapy with TNF inhibitors . Similar findings were noted for the risk for serious adverse events with JAK inhibitors in the combo therapy group vs the monotherapy group and anti–interleukin 1–based were associated with a significantly increased risk for serious adverse events.“The underlying disease and the agents being combined are among the relevant variables to be considered when individually choosing a combo therapy. Nevertheless, well-documented prognostic factors that could guide this decision are yet to be clarified,” the authors wrote. “Our data should help clinicians from a wide range of specialties in the management of such complex patients,” they added.This study was led by Anne-Laure Gérard and Matheus Vieira , Sorbonne Universités, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Centre national de références Maladies Autoinflammatoires rares et Amylose inflammatoire in Paris, France. It wasThe study’s reliance on hospital prescription data might have led to the underestimation of out-of-hospital events. The 90-day definition of combo therapy might have overlooked serious adverse events leading to early discontinuation. The median follow-up duration of 15 months was likely insufficient to assess the onset or recurrence of neoplasia, potentially underestimating rare or late-occurring adverse events.The study did not report any specific funding source. The authors reported no relevant conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Rheumatoid Arthritis (RA) Disease-Modifying Antirheumatic Drugs Dmards DMARD Hospitals Biologic Therapy Biologics Connective Tissue Disease Arthritis Joint Inflammation Artificial Intelligence Deep Learning AI NPL Machine Learning ML Natural Language Processing Artificial Neural Networks Europe European France French Glucocorticosteroids Glucocorticoid Therapy
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
How Tiny Bubbles Could Deliver Medication to the BrainTargeted therapy uses microbubbles to transport medication directly to its destination.
Read more »
PATINA Trial Shifts Paradigm in HER2+/ER+ Breast Cancer Treatment, Prolonging Survival With Targeted Combination TherapyDr Kathy Miller discusses how the PATINA trial reshapes treatment strategies for HER2+/ER+ breast cancer patients.
Read more »
Novel Combination Therapy Shows Promise in Killing Acute Myeloid Leukemia CellsResearchers at VCU Massey Comprehensive Cancer Center have identified a new treatment strategy that effectively kills AML cells by combining MCL-1 inhibitors with SRC kinase inhibitors.
Read more »
Gigi Hadid Paired This Polarizing Denim Trend With the Most Unexpected Shoe-and-Sock CombinationGigi Hadid was spotted in Paris in a polarizing denim trend and a super unexpected footwear choice. See the street style look, here.
Read more »
Targeted alpha therapy: Breakthrough in treating refractory skin cancerMetastatic melanoma is the most aggressive form of skin cancer. In an effort to achieve targeted therapy for metastatic melanoma, researchers recently developed a new radioactive drug that emits alpha particles.
Read more »
Immunotherapy may boost KRAS-targeted therapy in pancreatic cancerAdding immunotherapy to new KRAS inhibitors boosted responses in preclinical models, setting the stage for future trials of the combination strategy.
Read more »